Back to results
US 2026/0053905 A1Published application
Uveal melanoma vaccine
AssigneeUniversity of Virginia Patent Foundation
InventorCraig Slingluff
Life of this patent
Estimating the term…
Abstract
Disclosed are multi-peptide compositions and/or methods of use of the multi-peptide compositions for patients with resected (or definitively treated) high-risk uveal melanoma. Pharmaceutically acceptable embodiments administered to patients may raise an immune system response against uveal melanoma cells, leading to a decrease in uveal melanoma cell number. Further embodiments may take the form of an adjuvant therapy or a neoadjuvant therapy, as monotherapy or in combination with other therapies.
Claims15
A multi-peptide composition, comprising:
- (a) at least one peptide selected from each of the following source proteins:
- gp100, tyrosinase, MelanA/MART-1, MAGE-A1, MAGE-A3, MAGE-A10, and NY-ESO-1, wherein said peptides are selected for binding to Class I major histocompatibility complex (MHC) molecules;
- (b) at least one peptide selected from each of the following source proteins:
- gp100, tyrosinase, MelanA/MART-1, MAGE-A1, MAGE-A3, and MAGE-A6, wherein said peptides are selected for binding to Class II major histocompatibility complex (MHC) molecules;
- (c) at least one peptide comprising a mutated sequence from GNAQ or GNA11, wherein the mutation is at residue 209 and is selected from Q209L or Q209P.
2 more elements
A multi-peptide composition, comprising:
- (a) sixteen peptides selected for binding to Class I major histocompatibility complex (MHC) molecules, each peptide derived from a source protein selected from the group consisting of gp100, tyrosinase, MelanA/MART-1, MAGE-A1, MAGE-A3, MAGE-A10, NY-ESO-1, and PRAME;
- (b) eight peptides selected for binding to Class II major histocompatibility complex (MHC) molecules, each peptide derived from a source protein selected from the group consisting of gp100, tyrosinase, MelanA/MART-1, MAGE-A1, MAGE-A3, MAGE-A6, and PRAME;
- (c) two peptides comprising mutated sequences from GNAQ or GNA11, wherein the mutation is at residue 209 and is selected from Q209L or Q209P;
- wherein the composition consists of twenty-six peptides in total and is formulated as a pharmaceutically acceptable preparation.
1 more element
Dependencies are inferred from the claim text.